PMS-SALBUTAMOL SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

SALBUTAMOL (SALBUTAMOL SULFATE)

Tilgjengelig fra:

PHARMASCIENCE INC

ATC-kode:

R03AC02

INN (International Name):

SALBUTAMOL

Dosering :

1MG

Legemiddelform:

SOLUTION

Sammensetning:

SALBUTAMOL (SALBUTAMOL SULFATE) 1MG

Administreringsrute:

INHALATION

Enheter i pakken:

2.5ML

Resept typen:

Prescription

Terapeutisk område:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0108887007; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2010-05-04

Preparatomtale

PRODUCT MONOGRAPH
PR
PMS-SALBUTAMOL
Salbutamol Sulphate Inhalation Solution, BP
0.05%; 0.1%; 0.2%
0.5 mg/mL; 1 mg/mL; 2 mg/mL
BRONCHODILATOR
Beta
2
-adrenergic stimulant
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
Date of Revision:
August 10, 2018
www.pharmascience.com
Submission Control No: 217525
_ _
_pms-SALBUTAMOL Product Monograph Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
....................................................................................................
8
DOSAGE AND ADMINISTRATION
................................................................................
9
OVERDOSAGE
................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 11
STORAGE AND STABILITY
.........................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 13
PART II: SCIENTIFIC INFORMATION
...............................................................................
14
PHARMACEUTICAL INFORMATION
.........................................................................
14
CLINICAL TRIALS
...........................................................................................